What is the evidence supporting the use of cyclophosphamide in crescentic IgAN?
No direct evidence for cyclophosphamide in crescentic IgAN was found, but its use is inferred from broader IgA nephropathy treatment guidelines and mixed-study results. It may be considered in practice, especially within a broader immunosuppressive strategy for severe cases.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5281/zenodo.24299602
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00